The COMPPARE team was pleased to announce in August that the study had enrolled 750 patients, 25% of its 3,000-patient goal. COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).” The study compares the quality of life,…
The COMPPARE Coordinating Center is pleased to welcome 4 new sites and local principal investigators to the team. University of Chicago Medicine (site PI: Stan Liauw) ProCure Proton Therapy Center (site PI: Brian Chon, MD) University of Pennsylvania (site PI: Neha Vapiwala) Provision Healthcare (site PI:…
The 2019 COMPPARE Workshop: Recruitment, Retention, and Maximizing COMPPARE, was held March 22-24, 2019, at the Ritz-Carlton in beautiful Amelia Island, FL. Thanks to everyone who attended! Learning Objectives As a result of participation in this activity, participants were able to: describe the value of the COMPPARE…
COMPPARE patient stakeholders determined that a video would be a key element in our patient recruitment strategy. The Minority Engagement Group also decided that a real prostate cancer survivor was necessary to ensure authenticity and build a genuine connection with patients. Enter the exceptional Creative…
On February 2-4, 2018, members of the COMPPARE Consortium gathered at the beautiful Omni Amelia Island Plantation Resort in Amelia Island, FL, for a development workshop to prepare for the start of our PCORI contract on April 1. Dr. Nancy Mendenhall, the Principal Investigator (PI), and Dr. Ronald…
Nancy Mendenhall, MD, at the University of Florida Proton Therapy Institute, and Ronald Chen, MD, at the University of North Carolina at Chapel Hill, were awarded $11.9 million to directly compare the potential benefits and harms of proton therapy to standard radiation therapy when treating prostate cancer. Read…
